Peptide Asia makes research clear
Thymosin alpha-1. The immune evidence.
Thymosin alpha-1 affects immune signaling and has a history of medicine use abroad as thymalfasin. The guide explains clinical findings, including a large sepsis trial without a significant survival benefit, alongside safety and access questions.
Read about thymosin alpha-1What it is
A chain of 28 amino acids, the building blocks of proteins.
What was tested
The TESTS trial studied adults with sepsis, a severe response to infection.
What remains uncertain
A change in immune activity does not establish a general health benefit.
BPC-157. Repair claims in context.
BPC-157 is a synthetic peptide whose repair research comes mainly from animals and cells. Explore its amino-acid sequence, the experimental findings, and why limited human evidence leaves effectiveness and long-term safety unresolved.
Read about BPC-157MOTS-c. From cells to muscle.
The body makes MOTS-c, a peptide studied for its role in energy signaling. The guide separates muscle experiments and human blood measurements from the unanswered question of whether administering it helps people.
Read about MOTS-c
Semaglutide. The clinical picture.
Semaglutide has FDA-approved prescription medicines and large clinical trials in defined groups. Read what weight, cardiovascular, and kidney studies found, how side effects fit the picture, and why different preparations cannot be treated as equivalent.
Read about semaglutideClear context for every claim
Peptide Asia covers four compounds whose shared peptide label can hide large differences in evidence. Each guide explains what was studied, who or what was studied, and what remains unknown. The comparison page brings those findings together without ranking treatments. Questions about names, approval, and research quality have their own page. Read about the approach, or follow the linked publications in the references to see the original study setting and conclusions.